NASDAQ: AVBP

ArriVent BioPharma, Inc. Common Stock

Healthcare | Biotechnology

No licensed closing price on file for AVBP. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

ArriVent BioPharma, Inc. Common Stock (NASDAQ: AVBP) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-19 18:31 UTC.

What ArriVent BioPharma, Inc. Common Stock does

This company is a clinical-stage biopharmaceutical firm focused on developing cancer medicines addressing unmet patient needs. The company's lead candidate is firmonertinib, an investigational drug being tested in multiple clinical trials for non-small cell lung cancer patients with specific genetic mutations, and the company received Breakthrough Therapy Designation from the FDA for one indication. Beyond firmonertinib, the company is advancing a pipeline of antibody drug conjugates, including ARR-217, through partnerships and licensing agreements with other pharmaceutical firms.

Summarized from ArriVent BioPharma, Inc. Common Stock’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for AVBP are available in Oxford Ledge.
Open AVBP in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity

Source: SEC EDGAR · Filed 2026-06-22

Most recent filed transactions — June 2026:

2026-06-22DirectorNon-Qualified Stock Option (right to buy)Award13,562—
2026-06-22DirectorNon-Qualified Stock Option (right to buy)Award13,562—
2026-06-22DirectorNon-Qualified Stock Option (right to buy)Award13,562—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

MONTANOVA CAPITAL, LLC4,515,531$156.87M+2.6%
INFINITUM ASSET MANAGEMENT, LLC4,438,384$154.19M+7.0%
HHLR ADVISORS, LTD.3,929,117$136.50M0.0%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-03-13AuditorChanges in registrant's certifying accountantKPMG LLPAuthoritativeSEC 8-K →
2024-05-16Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-04-22Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
zacks.com2026-04-15
Fewer than five qualifying stories — full tape in the platform →

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for AVBP and 5,000+ tickers.

Create a free account — keep AVBP

For your agent

GET /api/data?ticker=AVBP

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt